

Jordan Feld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8445079/publications.pdf>

Version: 2024-02-01

354
papers

20,795
citations

10351

72
h-index

11899

134
g-index

373
all docs

373
docs citations

373
times ranked

18129
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic Fibrosis. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2584.	3.8	1,327
2	Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. <i>New England Journal of Medicine</i> , 2013, 368, 1867-1877.	13.9	992
3	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	13.9	945
4	Mechanism of action of interferon and ribavirin in treatment of hepatitis C. <i>Nature</i> , 2005, 436, 967-972.	13.7	878
5	Treatment of HCV with ABT-450/Ombitasvir and Dasabuvir with Ribavirin. <i>New England Journal of Medicine</i> , 2014, 370, 1594-1603.	13.9	816
6	Residual NADPH Oxidase and Survival in Chronic Granulomatous Disease. <i>New England Journal of Medicine</i> , 2010, 363, 2600-2610.	13.9	482
7	Hepatic Gene Expression Discriminates Responders and Nonresponders in Treatment of Chronic Hepatitis C Viral Infection. <i>Gastroenterology</i> , 2005, 128, 1437-1444.	0.6	433
8	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	3.7	370
9	Glecaprevir/Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018, 378, 354-369.	13.9	361
10	Autoimmune hepatitis: Effect of symptoms and cirrhosis on natural history and outcome. <i>Hepatology</i> , 2005, 42, 53-62.	3.6	308
11	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. <i>Gastroenterology</i> , 2015, 149, 1345-1360.	0.6	306
12	From non-A, non-B hepatitis to hepatitis C virus cure. <i>Journal of Hepatology</i> , 2015, 62, S87-S99.	1.8	284
13	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. <i>Gastroenterology</i> , 2019, 157, 1264-1278.e4.	0.6	252
14	Clinical trial: pilot study of metformin for the treatment of nonalcoholic steatohepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 172-182.	1.9	249
15	Increased caffeine consumption is associated with reduced hepatic fibrosis. <i>Hepatology</i> , 2010, 51, 201-209.	3.6	245
16	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alpha-Dependent Manner. <i>Gastroenterology</i> , 2010, 138, 325-335.e2.	0.6	243
17	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. <i>Hepatology</i> , 2007, 46, 1548-1563.	3.6	242
18	Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. <i>Hepatology</i> , 2015, 62, 79-86.	3.6	232

#	ARTICLE	IF	CITATIONS
19	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	3.7	231
20	Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2017, 66, 485-493.	1.8	225
21	Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. <i>Gastroenterology</i> , 2017, 153, 113-122.	0.6	215
22	Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. <i>Journal of Hepatology</i> , 2020, 72, 539-557.	1.8	208
23	Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 498-510.	5.2	180
24	Hepatitis B Virus-Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. <i>Gastroenterology</i> , 2016, 150, 684-695.e5.	0.6	178
25	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
26	Recommendations for the management of hepatitis C virus infection among people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1028-1038.	1.6	159
27	Integrated Quantum Dot Barcode Smartphone Optical Device for Wireless Multiplexed Diagnosis of Infected Patients. <i>ACS Nano</i> , 2015, 9, 3060-3074.	7.3	157
28	American Society of Clinical Oncology Provisional Clinical Opinion: Chronic Hepatitis B Virus Infection Screening in Patients Receiving Cytotoxic Chemotherapy for Treatment of Malignant Diseases. <i>Journal of Clinical Oncology</i> , 2010, 28, 3199-3202.	0.8	153
29	Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , 2015, 33, 2212-2220.	0.8	149
30	What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?. <i>Gastroenterology</i> , 2019, 156, 446-460.e2.	0.6	149
31	Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12 weeks. <i>Journal of Hepatology</i> , 2016, 64, 301-307.	1.8	147
32	Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 338-351.	8.2	144
33	The phenylpropanamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. <i>Antiviral Research</i> , 2007, 76, 168-177.	1.9	141
34	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. <i>Hepatology</i> , 2011, 53, 32-41.	3.6	140
35	Early Changes in Natural Killer Cell Function Indicate Virologic Response to Interferon Therapy for Hepatitis C. <i>Gastroenterology</i> , 2011, 141, 1231-1239.e2.	0.6	139
36	Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 550-556.	3.6	137

#	ARTICLE	IF	CITATIONS
37	Hepatitis C Virus Therapeutic Development: In Pursuit of "Perfectovir". <i>Clinical Infectious Diseases</i> , 2015, 60, 1829-1836.	2.9	134
38	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1253-1263.e2.	0.6	131
39	Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B. <i>Hepatology</i> , 2020, 71, 539-548.	3.6	128
40	Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. <i>Journal of Hepatology</i> , 2018, 68, 92-99.	1.8	126
41	Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. <i>Gastroenterology</i> , 2019, 156, 1683-1692.e1.	0.6	121
42	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1109-1115.	1.5	116
43	Immigration and viral hepatitis. <i>Journal of Hepatology</i> , 2015, 63, 515-522.	1.8	114
44	Combined ursodeoxycholic acid (<scp>UDCA</scp>) and fenofibrate in primary biliary cholangitis patients with incomplete <scp>UDCA</scp> response may improve outcomes. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 283-293.	1.9	109
45	Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). <i>Gut</i> , 2019, 68, 2206-2213.	6.1	109
46	Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. <i>Gastroenterology</i> , 2010, 139, 154-162.e4.	0.6	108
47	Hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients receiving rituximab for lymphoma: a meta-analysis. <i>Journal of Viral Hepatitis</i> , 2015, 22, 842-849.	1.0	107
48	Clinical Validation of Quantum Dot Barcode Diagnostic Technology. <i>ACS Nano</i> , 2016, 10, 4742-4753.	7.3	107
49	Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. <i>Hepatology</i> , 2012, 55, 39-48.	3.6	103
50	Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. <i>Journal of Hepatology</i> , 2016, 65, 33-39.	1.8	103
51	Hepatic abnormalities in patients with chronic granulomatous disease. <i>Hepatology</i> , 2007, 45, 675-683.	3.6	102
52	An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 359-375.	1.8	101
53	Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C. <i>Gastroenterology</i> , 2007, 132, 733-744.	0.6	100
54	Cell-Type Specific Gene Expression Signature in Liver Underlies Response to Interferon Therapy in Chronic Hepatitis C Infection. <i>Gastroenterology</i> , 2010, 138, 1123-1133.e3.	0.6	99

#	ARTICLE	IF	CITATIONS
55	Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 3698-3715.	0.8	99
56	Prevalence, Correlates, and Viral Dynamics of Hepatitis Delta among Injection Drug Users. <i>Journal of Infectious Diseases</i> , 2010, 202, 845-852.	1.9	96
57	Hepatitis B Virus Screening Before Chemotherapy for Lymphoma: A Cost-Effectiveness Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 3167-3173.	0.8	94
58	Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. <i>American Journal of Gastroenterology</i> , 2017, 112, 1298-1308.	0.2	93
59	The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. <i>Cmaj</i> , 2018, 190, E677-E687.	0.9	93
60	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 183-192.	2.4	90
61	Epidemiology of autoimmune liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 1118-1128.	1.4	89
62	Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1927.	3.8	89
63	Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 867-876.	1.9	88
64	Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 192-201.	5.2	87
65	Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. <i>Nature Communications</i> , 2019, 10, 481.	5.8	86
66	Hepatic Involvement and Portal Hypertension Predict Mortality in Chronic Granulomatous Disease. <i>Gastroenterology</i> , 2008, 134, 1917-1926.	0.6	84
67	Hepatitis C " identifying patients with progressive liver injury. <i>Hepatology</i> , 2006, 43, S194-S206.	3.6	82
68	Identifying cirrhosis, decompensated cirrhosis and hepatocellular carcinoma in health administrative data: A validation study. <i>PLoS ONE</i> , 2018, 13, e0201120.	1.1	82
69	Cost Effectiveness of Hepatocellular Carcinoma Surveillance After a Sustained Virologic Response to Therapy in Patients With Hepatitis C Virus Infection and Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1840-1849.e16.	2.4	82
70	Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. <i>Clinical Infectious Diseases</i> , 2016, 63, 1479-1481.	2.9	81
71	Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. <i>Liver International</i> , 2021, 41, 456-463.	1.9	81
72	Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. <i>Liver International</i> , 2017, 37, 5-18.	1.9	76

#	ARTICLE	IF	CITATIONS
73	Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 649-657.	3.7	76
74	Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. <i>CMAJ Open</i> , 2016, 4, E605-E614.	1.1	74
75	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74
76	Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 421-430.e6.	2.4	72
77	Hepatitis B virus DNA prediction rules for hepatitis B e antigenâ€“negative chronic hepatitis B. <i>Hepatology</i> , 2007, 46, 1057-1070.	3.6	71
78	A research agenda for curing chronic hepatitis B virus infection. <i>Hepatology</i> , 2018, 67, 1127-1131.	3.6	70
79	Endpoints of therapy in chronic hepatitis B. <i>Hepatology</i> , 2009, 49, S96-S102.	3.6	68
80	Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. <i>Journal of Hepatology</i> , 2021, 74, 1053-1063.	1.8	68
81	An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 19-34.	0.8	67
82	Inducing Hepatitis C Virus Resistance After Pig Liver Transplantationâ€“A Proof of Concept of Liver Graft Modification Using Warm Ex Vivo Perfusion. <i>American Journal of Transplantation</i> , 2017, 17, 970-978.	2.6	66
83	Cost-effectiveness of screening for hepatitis C in Canada. <i>Cmaj</i> , 2015, 187, E110-E121.	0.9	65
84	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	3.6	64
85	Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 406-417.	3.7	64
86	Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study). <i>Gastroenterology</i> , 2022, 162, 757-771.e4.	0.6	63
87	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1130-1137.	2.4	62
88	Hepatic Cellâ€“Type Specific Gene Expression Better Predicts HCV Treatment Outcome Than IL28B Genotype. <i>Gastroenterology</i> , 2012, 142, 1122-1131.e1.	0.6	61
89	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. <i>Hepatology</i> , 2013, 57, 2124-2134.	3.6	61
90	Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1821-1830.e6.	2.4	61

#	ARTICLE	IF	CITATIONS
91	New therapeutic agents for chronic hepatitis B. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e10-e21.	4.6	59
92	Acute Spontaneous Tumor Lysis Syndrome in Adenocarcinoma of the Lung. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2000, 23, 491-493.	0.6	58
93	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	1.6	58
94	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	1.6	54
95	Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. <i>Nature Genetics</i> , 2022, 54, 1103-1116.	9.4	54
96	Abnormal Intestinal Permeability in Primary Biliary Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1607-1613.	1.1	53
97	Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen. <i>Antiviral Therapy</i> , 2018, 23, 211-217.	0.6	53
98	Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. <i>Clinical Infectious Diseases</i> , 2020, 71, e115-e124.	2.9	53
99	Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B Report From the 2019 EASL AASLD HBV Treatment Endpoints Conference. <i>Hepatology</i> , 2020, 71, 1070-1092.	3.6	52
100	S-Adenosyl Methionine Improves Early Viral Responses and Interferon-Stimulated Gene Induction in Hepatitis C Nonresponders. <i>Gastroenterology</i> , 2011, 140, 830-839.e3.	0.6	51
101	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. <i>Gut</i> , 2014, 63, 161-169.	6.1	51
102	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	49
103	Approaches for simplified HCV diagnostic algorithms. <i>Journal of the International AIDS Society</i> , 2018, 21, e25058.	1.2	47
104	Interferon-Free Strategies with a Nucleoside/Nucleotide Analogue. <i>Seminars in Liver Disease</i> , 2014, 34, 037-046.	1.8	45
105	Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 25-35.	3.7	45
106	Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. <i>Clinical Infectious Diseases</i> , 2016, 63, 776-783.	2.9	45
107	Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 494-500.	3.7	45
108	New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. <i>Hepatology</i> , 2003, 38, 545-553.	3.6	44

#	ARTICLE	IF	CITATIONS
109	Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 887-894.	1.9	44
110	Liver injury is associated with mortality in sickle cell disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 912-921.	1.9	44
111	Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1168-1176.	1.4	44
112	Diagnosing Antibiotic Resistance Using Nucleic Acid Enzymes and Gold Nanoparticles. <i>ACS Nano</i> , 2021, 15, 9379-9390.	7.3	44
113	HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 856-864.	3.7	43
114	Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. <i>Annals of Hepatology</i> , 2012, 11, 426-439.	0.6	41
115	Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2021, 72, 202-211.	2.9	41
116	A Canadian screening program for hepatitis C: Is now the time?. <i>Cmaj</i> , 2013, 185, 1325-1328.	0.9	40
117	Is there sufficient evidence to recommend antiviral therapy in hepatitis C?. <i>Journal of Hepatology</i> , 2014, 60, 191-196.	1.8	40
118	The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection. <i>Gut</i> , 2016, 65, 1347-1358.	6.1	40
119	Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1 and compensated cirrhosis or advanced fibrosis. <i>Liver International</i> , 2018, 38, 443-450.	1.9	40
120	Role of Serologic and Molecular Diagnostic Assays in Identification and Management of Hepatitis C Virus Infection. <i>Journal of Clinical Microbiology</i> , 2016, 54, 265-273.	1.8	38
121	Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection. <i>Hepatology</i> , 2019, 69, 2338-2348.	3.6	37
122	Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy001.	0.4	36
123	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990-2009. <i>PLoS ONE</i> , 2012, 7, e40917.	1.1	36
124	Second generation direct-acting antivirals - Do we expect major improvements?. <i>Journal of Hepatology</i> , 2016, 65, S130-S142.	1.8	35
125	Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 231-243.	1.9	35
126	The impact of SVR from direct-acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk. <i>Journal of Viral Hepatitis</i> , 2020, 27, 781-793.	1.0	34

#	ARTICLE	IF	CITATIONS
127	The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals. <i>Journal of Virus Eradication</i> , 2019, 5, 60-66.	0.3	34
128	Hepatitis B e Antigen-Positive Chronic Hepatitis B: Natural History and Treatment. <i>Seminars in Liver Disease</i> , 2006, 26, 116-129.	1.8	32
129	No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA $\leq 6,000,000$ IU/mL. <i>Hepatology</i> , 2016, 63, 28-30.	3.6	32
130	HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. <i>Journal of Virological Methods</i> , 2017, 245, 14-18.	1.0	32
131	How does coffee prevent liver fibrosis? biological plausibility for recent epidemiological observations. <i>Hepatology</i> , 2014, 60, 464-467.	3.6	30
132	Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters. <i>Gut</i> , 2015, 64, 322-331.	6.1	30
133	Lipopolysaccharide and Tumor Necrosis Factor Alpha Inhibit Interferon Signaling in Hepatocytes by Increasing Ubiquitin-Like Protease 18 (USP18) Expression. <i>Journal of Virology</i> , 2016, 90, 5549-5560.	1.5	30
134	Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. <i>Clinical Infectious Diseases</i> , 2017, 65, 680-683.	2.9	30
135	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. <i>Journal of Hepatology</i> , 2020, 72, 431-440.	1.8	30
136	Poor Recognition of Risk Factors for Hepatitis B by Physicians Prescribing Immunosuppressive Therapy: A Call for Universal Rather than Risk-Based Screening. <i>PLoS ONE</i> , 2015, 10, e0120749.	1.1	29
137	Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy. <i>Liver International</i> , 2015, 35, 1923-1933.	1.9	28
138	Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 502-513.	1.0	28
139	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2541-2551.e2.	2.4	28
140	HCV persistence: Cure is still a four letter word. <i>Hepatology</i> , 2005, 41, 23-25.	3.6	27
141	Virological responses during treatment for recent hepatitis C virus. <i>Aids</i> , 2012, 26, 1653-1661.	1.0	27
142	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	1.8	27
143	Ribavirin improves the IFN- γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. <i>Hepatology</i> , 2014, 60, 1160-1169.	3.6	26
144	Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs. <i>Cancer</i> , 2020, 126, 1550-1558.	2.0	26

#	ARTICLE	IF	CITATIONS
145	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	2.9	26
146	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	2.0	26
147	Antiviral therapy for hepatitis B virus infections: new targets and technical challenges. <i>Journal of Clinical Virology</i> , 2002, 25, 267-283.	1.6	25
148	Does Antiviral Therapy for Chronic Hepatitis B Reduce the Risk of Hepatocellular Carcinoma?. <i>Seminars in Liver Disease</i> , 2013, 33, 157-166.	1.8	25
149	The beginning of the end: What is the future of interferon therapy for chronic hepatitis C?. <i>Antiviral Research</i> , 2014, 105, 32-38.	1.9	25
150	A Systematic Review and Meta-Analysis of Health Utilities in Patients With Chronic Hepatitis C. <i>Value in Health</i> , 2020, 23, 127-137.	0.1	24
151	Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 169-184.	3.7	24
152	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1005-1021.	1.9	24
153	Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1228-1234.	2.9	23
154	Model-based projection of health and economic effects of screening for hepatitis C in Canada. <i>CMAJ Open</i> , 2017, 5, E662-E672.	1.1	23
155	Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update. <i>BMJ Open</i> , 2019, 9, e027491.	0.8	23
156	Simplification of Care for Chronic Hepatitis C Virus Infection. <i>Seminars in Liver Disease</i> , 2020, 40, 392-402.	1.8	23
157	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. <i>Hepatology</i> , 2021, 73, 2124-2140.	3.6	23
158	Flu-like Symptoms and Associated Immunological Response Following Therapy with Botulinum Toxins. <i>Neurotoxicity Research</i> , 2013, 24, 298-306.	1.3	22
159	Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. <i>Journal of Hepatology</i> , 2015, 62, 294-302.	1.8	22
160	Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. <i>Clinical Infectious Diseases</i> , 2017, 65, 13-19.	2.9	22
161	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	1.6	22
162	The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. <i>European Radiology</i> , 2019, 29, 1039-1047.	2.3	22

#	ARTICLE	IF	CITATIONS
163	Controlled Human Infection Model “Fast Track to HCV Vaccine?”. <i>New England Journal of Medicine</i> , 2021, 385, 1235-1240.	13.9	22
164	Defining and grading HBV reactivation. <i>Clinical Liver Disease</i> , 2015, 5, 35-38.	1.0	21
165	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. <i>Diabetes Care</i> , 2018, 41, 1251-1259.	4.3	21
166	Population-based estimate of hepatitis C virus prevalence in Ontario, Canada. <i>PLoS ONE</i> , 2018, 13, e0191184.	1.1	21
167	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1969-1979.	2.9	21
168	Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis. <i>CMAJ Open</i> , 2017, 5, E97-E108.	1.1	20
169	Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. <i>Hepatology Communications</i> , 2021, 5, 478-490.	2.0	20
170	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1027-1035.	1.9	19
171	The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2014, 21, 568-577.	1.0	19
172	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 46-55.	1.9	19
173	Hepatitis C Core-Antigen Testing from Dried Blood Spots. <i>Viruses</i> , 2019, 11, 830.	1.5	19
174	Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 2369-2376.	2.9	19
175	The emergency department as a setting-specific opportunity for population-based hepatitis C screening: An economic evaluation. <i>Liver International</i> , 2020, 40, 1282-1291.	1.9	19
176	The impact of the first, second and third waves of covid-19 on hepatitis B and C testing in Ontario, Canada. <i>Journal of Viral Hepatitis</i> , 2022, 29, 205-208.	1.0	19
177	Protein Interferon-Stimulated Gene 15 Conjugation Delays but Does Not Overcome Coronavirus Proliferation in a Model of Fulminant Hepatitis. <i>Journal of Virology</i> , 2014, 88, 6195-6204.	1.5	18
178	Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Hepatology</i> , 2014, 61, 482-491.	1.8	18
179	Race or genetic makeup for hepatitis C virus treatment decisions?. <i>Hepatology</i> , 2017, 65, 2124-2125.	3.6	18
180	Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2020, 158, 1185-1190.	0.6	18

#	ARTICLE	IF	CITATIONS
181	Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. <i>Hepatology Communications</i> , 2021, 5, 911-922.	2.0	18
182	Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2021, 12, 648420.	2.2	18
183	Acute Hepatitis C: Management in the Rapidly Evolving World of HCV. <i>Current Gastroenterology Reports</i> , 2014, 16, 371.	1.1	17
184	Treatment of hepatitis B virus with combination therapy now and in the future. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2017, 31, 347-355.	1.0	17
185	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2019, 26, 856-865.	1.0	17
186	Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. <i>European Radiology</i> , 2020, 30, 3735-3747.	2.3	17
187	Evaluation of Dried Blood Spot Testing for SARS-CoV-2 Serology Using a Quantitative Commercial Assay. <i>Viruses</i> , 2021, 13, 962.	1.5	17
188	Symptomatic and Pathophysiologic Predictors of Hepatitis C Virus Progression in Pediatric Patients. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 724-727.	1.1	16
189	Arresting the time-dependent H ₂ O ₂ mediated synthesis of gold nanoparticles for analytical detection and preparative chemistry. <i>Journal of Materials Chemistry B</i> , 2013, 1, 4048.	2.9	16
190	Hepatitis C Virus Diagnostics: The Road to Simplification. <i>Clinical Liver Disease</i> , 2018, 12, 125-129.	1.0	16
191	Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study. <i>Cmaj</i> , 2020, 192, E1299-E1305.	0.9	16
192	Direct-Acting Antivirals for Hepatitis C Virus (HCV): The Progress Continues. <i>Current Drug Targets</i> , 2017, 18, 851-862.	1.0	16
193	Is There a Role for Ribavirin in the Era of Hepatitis C Virus Direct-Acting Antivirals?. <i>Gastroenterology</i> , 2012, 142, 1356-1359.	0.6	15
194	The Effectiveness of Ultrasound Surveillance for Hepatocellular Carcinoma in a Canadian Centre and Determinants of Its Success. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 267-273.	0.8	15
195	Psychiatric Care During Hepatitis C Treatment: The Changing Role of Psychiatrists in the Era of Direct-Acting Antivirals. <i>American Journal of Psychiatry</i> , 2015, 172, 512-516.	4.0	15
196	Replication and Oncolytic Activity of an Avian Orthoreovirus in Human Hepatocellular Carcinoma Cells. <i>Viruses</i> , 2017, 9, 90.	1.5	15
197	Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission. <i>Journal of Hepatology</i> , 2022, 77, 1256-1264.	1.8	15
198	Liver stiffness increases acutely during sickle cell vaso-occlusive crisis. <i>American Journal of Hematology</i> , 2013, 88, E250-4.	2.0	14

#	ARTICLE	IF	CITATIONS
199	World Gastroenterology Organisation Global Guideline Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 691-703.	1.1	14
200	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , 2015, 4, 95.	0.8	14
201	Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 429-444.	1.0	13
202	I drink for my liver, Doc: emerging evidence that coffee prevents cirrhosis. <i>F1000Research</i> , 2015, 4, 95.	0.8	13
203	Implications of Manganese in Chronic Acquired Hepatocerebral Degeneration. <i>Annals of Hepatology</i> , 2019, 18, 274-278.	0.6	13
204	Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection. <i>Cells</i> , 2019, 8, 317.	1.8	13
205	Hepatitis C models of care: approaches to elimination. <i>Canadian Liver Journal</i> , 2020, 3, 165-176.	0.3	13
206	The viral hepatitis B care cascade: A population-based comparison of immigrant groups. <i>Hepatology</i> , 2022, 75, 673-689.	3.6	13
207	What Comes First: Treatment of Viral Hepatitis or Liver Cancer?. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1041-1049.	1.1	12
208	Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1451-1458.e4.	2.4	12
209	Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 639-652.	1.1	11
210	Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. <i>Journal of Hepatology</i> , 2017, 67, 700-707.	1.8	11
211	Wait Time for Curative Intent Radio Frequency Ablation is Associated with Increased Mortality in Patients with Early Stage Hepatocellular Carcinoma. <i>Annals of Hepatology</i> , 2017, 16, 765-771.	0.6	11
212	Diagnosis of Chronic Hepatitis B Pericomplication: Risk factors and Trends Over Time. <i>Hepatology</i> , 2021, 73, 2141-2154.	3.6	11
213	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. <i>Hepatology</i> , 2021, 73, 1637-1651.	3.6	11
214	Global Utilization Trends of Direct Acting Antivirals (DAAs) during the COVID-19 Pandemic: A Time Series Analysis. <i>Viruses</i> , 2021, 13, 1314.	1.5	11
215	Risk for Hepatocellular Carcinoma After Hepatitis C Virus Antiviral Therapy With Direct-Acting Antivirals: Case Closed?. <i>Gastroenterology</i> , 2017, 153, 890-892.	0.6	11
216	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	1.4	10

#	ARTICLE	IF	CITATIONS
217	Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 631-639.	1.0	10
218	Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1127-1138.	1.0	10
219	Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patients. <i>Scientific Reports</i> , 2020, 10, 11344.	1.6	10
220	Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry. <i>Clinical Infectious Diseases</i> , 2021, 72, e799-e805.	2.9	10
221	Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework. <i>Journal of Virus Eradication</i> , 2018, 4, 193-195.	0.3	10
222	Death from Liver Failure despite Lamivudine Prophylaxis during R-CHOP Chemotherapy due to Rapid Emergence M204 Mutations. <i>Case Reports in Hepatology</i> , 2013, 2013, 1-5.	0.4	9
223	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. <i>PLoS ONE</i> , 2013, 8, e80003.	1.1	9
224	Hepatitis B Reactivation: The Controversies Continue. <i>Digestive Diseases</i> , 2017, 35, 351-358.	0.8	9
225	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
226	Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. <i>Liver International</i> , 2021, 41, 1775-1788.	1.9	9
227	Low and standard dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1018-1027.	1.9	8
228	Optimal preservation of liver biopsy samples for downstream translational applications. <i>Hepatology International</i> , 2013, 7, 758-766.	1.9	8
229	Hepatocellular Carcinoma in a Large Canadian Urban Centre: Stage at Treatment and Its Potential Determinants. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 150-154.	0.8	8
230	Absolute Ligand Discrimination by Dimeric Signaling Receptors. <i>Biophysical Journal</i> , 2016, 111, 917-920.	0.2	8
231	Resistance testing: Interpretation and incorporation into HCV treatment algorithms. <i>Clinical Liver Disease</i> , 2017, 9, 115-120.	1.0	8
232	Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. <i>Journal of Viral Hepatitis</i> , 2017, 24, 280-286.	1.0	8
233	Expert Opinion on Managing Chronic HCV in Patients with Non-Hodgkin Lymphoma and other Extrahepatic Malignancies. <i>Antiviral Therapy</i> , 2018, 23, 23-33.	0.6	8
234	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. <i>Gastroenterology</i> , 2020, 158, 2028-2032.	0.6	8

#	ARTICLE	IF	CITATIONS
235	High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence. <i>American Journal of Gastroenterology</i> , 2021, 116, 1896-1904.	0.2	8
236	The Inflammatory Cytokine Profile Associated With Liver Damage Is Broader and Stronger in Patients With Chronic Hepatitis B Compared to Patients With Acute Hepatitis B. <i>Journal of Infectious Diseases</i> , 2022, 225, 470-475.	1.9	8
237	Hepatitis B virus and hepatitis C virus treatment and management in patients receiving immune-modifying agents. <i>Current Opinion in Rheumatology</i> , 2014, 26, 395-403.	2.0	7
238	Hepatitis B Reactivation With Hepatitis C Treatment: Bringing Some Clarity to the Black Box. <i>Gastroenterology</i> , 2018, 154, 795-798.	0.6	7
239	IL-15 and IFN- β signal through the ERK pathway to inhibit HCV replication, independent of type I IFN signaling. <i>Cytokine</i> , 2019, 124, 154439.	1.4	7
240	Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2019, 25, 697-704.	0.5	7
241	The basis of liver regeneration: A systems biology approach. <i>Annals of Hepatology</i> , 2019, 18, 422-428.	0.6	7
242	A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. <i>Vaccine</i> , 2020, 38, 6864-6867.	1.7	7
243	Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. <i>BMC Public Health</i> , 2020, 20, 1345.	1.2	7
244	Remaining challenges in HCV elimination. <i>Journal of Hepatology</i> , 2021, 74, 964-965.	1.8	7
245	Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2021, 72, 780-786.	2.9	7
246	Immunomodulation and RNA interference alter hepatitis B virus-specific CD8 T cell recognition of infected HepG2-TCP. <i>Hepatology</i> , 2022, 75, 1539-1550.	3.6	7
247	Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). <i>Canadian Liver Journal</i> , 2022, 5, 61-90.	0.3	7
248	Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. <i>Hepatology</i> , 2022, 76, 775-787.	3.6	7
249	Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. <i>Journal of Hepatology</i> , 2022, 77, 947-956.	1.8	7
250	Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. <i>Liver International</i> , 2018, 38, 1571-1575.	1.9	6
251	Hepatitis C: A Canadian perspective. <i>Canadian Liver Journal</i> , 2018, 1, 1-3.	0.3	6
252	The Ubiquitin-Specific Protease 18 Promotes Hepatitis C Virus Production by Increasing Viral Infectivity. <i>Mediators of Inflammation</i> , 2019, 2019, 1-12.	1.4	6

#	ARTICLE	IF	CITATIONS
253	The health impact of delaying direct-acting antiviral treatment for chronic hepatitis C: A decision-analytic approach. <i>Liver International</i> , 2020, 40, 51-59.	1.9	6
254	Peri-complication diagnosis of hepatitis C infection: Risk factors and trends over time. <i>Liver International</i> , 2021, 41, 33-47.	1.9	6
255	Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 674-681.	2.4	6
256	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1526-1538.	1.0	6
257	Evolution of Therapy for Chronic Hepatitis B: Progressing from the Simple to the Complex. <i>Annals of Internal Medicine</i> , 2007, 147, 806.	2.0	5
258	Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response. <i>Scientific Reports</i> , 2016, 6, 35410.	1.6	5
259	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	1.3	5
260	Extending a Helping Hand: Addressing Hepatitis C in Economic Migrants and Refugees. <i>Annals of Hepatology</i> , 2018, 17, 8-10.	0.6	5
261	Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 260-267.	1.0	5
262	Clinical significance of quantitative e antigen in a cohort of hepatitis B virus-infected children and adults in North America. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1042-1056.	1.0	5
263	Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study. <i>CMAJ Open</i> , 2021, 9, E897-E906.	1.1	5
264	Risk of infections during interferon-based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1057-1064.	1.4	4
265	Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.	1.4	4
266	Pitfalls in measuring temporal trends for late diagnosis of viral hepatitis. <i>Journal of Hepatology</i> , 2019, 71, 1251-1254.	1.8	4
267	PS-139-Liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. <i>Journal of Hepatology</i> , 2019, 70, e89.	1.8	4
268	Host Genetic Variant in CXCL16 May Be Associated With Hepatitis B Virus-Related Acute Liver Failure. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2019, 7, 477-479.e4.	2.3	4
269	Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B. <i>Liver International</i> , 2019, 39, 1418-1427.	1.9	4
270	Validating viral hepatitis B and C diagnosis codes: a retrospective analysis using Ontario's health administrative data. <i>Canadian Journal of Public Health</i> , 2021, 112, 502-512.	1.1	4

#	ARTICLE	IF	CITATIONS
271	Impact of COVID-19 on Prescribing Trends of Direct-Acting Antivirals for the Treatment of Hepatitis C in Ontario, Canada. <i>American Journal of Gastroenterology</i> , 2021, 116, 1738-1740.	0.2	4
272	Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. <i>Canadian Liver Journal</i> , 2021, 4, 257-274.	0.3	4
273	Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments. <i>Clinical Infectious Diseases</i> , 2022, 75, 3-10.	2.9	4
274	Determinants of Ligand Specificity and Functional Plasticity in Type I Interferon Signaling. <i>Frontiers in Immunology</i> , 2021, 12, 748423.	2.2	4
275	Vaccination at the forefront of the fight against hepatitis B and C. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 87-88.	8.2	4
276	Interferon responses and spontaneous HCV clearance: Is it all a matter of fat?. <i>Journal of Hepatology</i> , 2012, 57, 3-5.	1.8	3
277	Editorial Commentary: Sustained Virologic Response for Patients With Hepatitis C-Related Cirrhosis: A Major Milestone, but Not Quite a Cure. <i>Clinical Infectious Diseases</i> , 2013, 57, 237-239.	2.9	3
278	Management of HCV in Cirrhosis—a Rapidly Evolving Landscape. <i>Current Gastroenterology Reports</i> , 2015, 17, 443.	1.1	3
279	GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection. <i>American Journal of Gastroenterology</i> , 2016, 111, S388.	0.2	3
280	One small SNP for receptor virus entry, one giant leap for hepatitis B?. <i>Gut</i> , 2016, 65, 1395-1397.	6.1	3
281	Inpatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. <i>Journal of Viral Hepatitis</i> , 2018, 25, 344-353.	1.0	3
282	The 7th Canadian Symposium on Hepatitis C Virus: “Toward Elimination of HCV: How to Get There” <i>Canadian Liver Journal</i> , 2018, 1, 139-152.	0.3	3
283	FRI-190-Incidence and predictors of flares after discontinuing nucleos (t) ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP study. <i>Journal of Hepatology</i> , 2019, 70, e474.	1.8	3
284	Hepatitis C virus infection in mothers and children. <i>Canadian Liver Journal</i> , 2019, 2, 210-224.	0.3	3
285	Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. <i>Virology Journal</i> , 2020, 17, 140.	1.4	3
286	Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. <i>Value in Health</i> , 2022, 25, 247-256.	0.1	3
287	HCV elimination: It will take a village and then some. <i>Journal of Hepatology</i> , 2020, 72, 601-603.	1.8	3
288	Hepatitis B reactivation in patients with solid tumors: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 138-138.	0.8	3

#	ARTICLE	IF	CITATIONS
289	Update on the Risk of Primary and Recurrent HCC With the Use of DAA Therapy for HCV Infection. <i>Gastroenterology and Hepatology</i> , 2019, 15, 303-306.	0.2	3
290	The mean attributable health care costs associated with hepatitis B virus in Ontario, Canada: A matched cohort study. <i>Canadian Liver Journal</i> , 2022, 5, 339-361.	0.3	3
291	Characteristics of Older Patients With Immunotolerant Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1503-1512.e4.	2.4	3
292	HBV treatment in a patient who will be receiving immunosuppressive therapy. <i>Clinical Liver Disease</i> , 2013, 2, 34-37.	1.0	2
293	Hepatitis C virus infection. <i>Cmaj</i> , 2015, 187, 1159-1159.	0.9	2
294	Cure prevents more than transmission of hepatitis C virus. <i>Hepatology</i> , 2016, 64, 1003-1004.	3.6	2
295	Editorial: fenofibrate as secondâ€line therapy in high risk <scp>PBC</scp> â€“ more answers or more questions? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 649-650.	1.9	2
296	Overcoming the resistance to resistance testing: Collecting the data. <i>Liver International</i> , 2017, 37, 506-508.	1.9	2
297	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. <i>Journal of Hepatology</i> , 2019, 70, e110.	1.8	2
298	THU-393-HCV infection in Canadian immigrants: Characteristics and treatment outcomes of the CANUHC cohort. <i>Journal of Hepatology</i> , 2019, 70, e328.	1.8	2
299	Hostâ€pathogen interactions in chronic HBV infection and transplantation of HCV-positive organs. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 77-78.	8.2	2
300	HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype Definition. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 259-261.	2.4	2
301	The 9th Canadian Symposium on Hepatitis C Virus: Advances in HCV research and treatment towards elimination. <i>Canadian Liver Journal</i> , 2021, 4, 59-71.	0.3	2
302	Hepatitis C virus infection in First Nations populations in Ontario from 2006 to 2014: a population-based retrospective cohort analysis. <i>CMAJ Open</i> , 2021, 9, E886-E896.	1.1	2
303	Sofosbuvir + Ribavirin With or Without Peginterferon Is Well-Tolerated and Associated with High SVR Rates: Integrated Results from 4 Phase 3 Trials in HCV Genotype 1-6. <i>American Journal of Gastroenterology</i> , 2013, 108, S123.	0.2	2
304	Birth cohort hepatitis C antibody prevalence in real-world screening settings in Ontario. <i>Canadian Liver Journal</i> , 2022, 5, 362-371.	0.3	2
305	Hepatitis B Biomarkers: Clinical Significance of the Old and the New. <i>Current Hepatitis Reports</i> , 2010, 9, 187-196.	0.3	1
306	Vascular Diseases of the Liver. , 2012, , 315-328.		1

#	ARTICLE	IF	CITATIONS
307	Commentary: non-haemodynamic effects of beta-blockers in cirrhosis - more than meets the eye?. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 652-652.	1.9	1
308	Commentary: what factors are important in diagnosing hepatic fibrosis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 545-546.	1.9	1
309	Does Eltrombopag Really ENABLE SVR?. <i>Gastroenterology</i> , 2014, 146, 339-342.	0.6	1
310	Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-7.	0.8	1
311	Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2016, 23, 340-347.	1.0	1
312	503 High SVR Rates in Patients with Genotype 4 Chronic Hepatitis C Infection and Compensated Cirrhosis With Ombitasvir/Paritaprevir/Ritonavir Co-Administered With Ribavirin (AGATE-I). <i>Gastroenterology</i> , 2016, 150, S1037.	0.6	1
313	812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial. <i>Gastroenterology</i> , 2016, 150, S1267-S1268.	0.6	1
314	Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C in Patients Aged 65 Years or Older: A Retrospective Analysis of Phase 3 Studies. <i>Gastroenterology</i> , 2017, 152, S1097.	0.6	1
315	Editorial: hepatitis C direct acting antiviral agents and the kidney” authors” reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 379-380.	1.9	1
316	Resolved HBV and anti-CD20 therapy. <i>Blood</i> , 2019, 133, 104-106.	0.6	1
317	Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 19, 2398-2406.e1.	2.4	1
318	Letter to the Editor: Safety First: Favoring Prophylactic/Preemptive Over Delayed Treatment in D+/R” Transplants. <i>Hepatology</i> , 2020, 72, 787-787.	3.6	1
319	Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 51-60.	1.0	1
320	The 8th Canadian Symposium on Hepatitis C virus: “Improving diagnosis and linkage to care” Canadian Liver Journal, 2020, 3, 3-14.	0.3	1
321	A collaborative approach to hepatitis C testing in two First Nations communities of Northwest Ontario. <i>Canadian Liver Journal</i> , 0, , .	0.3	1
322	The lighter side of myeloma: an easily overlooked diagnosis. <i>Gut</i> , 2005, 54, 1376-1376.	6.1	0
323	Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions. <i>Hepatitis Monthly</i> , 2011, 11, .	0.1	0
324	HCV infection on-treatment viral kinetics: Do they still have a role?. <i>Clinical Liver Disease</i> , 2012, 1, 51-53.	1.0	0

#	ARTICLE	IF	CITATIONS
325	Tratamiento del VHB en pacientes que van a recibir terapia inmunosupresora. <i>Clinical Liver Disease</i> , 2013, 2, S28Å-S32Å.	1.0	0
326	Sigue desempeñando algún papel la cinética viral durante el tratamiento de la infección por el VHC?. <i>Clinical Liver Disease</i> , 2013, 2, S24Å-S27Å.	1.0	0
327	Reply to: "Evidence recommending antiviral therapy in hepatitis C". <i>Journal of Hepatology</i> , 2014, 60, 1102-1103.	1.8	0
328	Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection. <i>International Journal of Drug Policy</i> , 2015, , 101669.	1.6	0
329	Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral. <i>International Journal of Drug Policy</i> , 2015, , 101671.	1.6	0
330	751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin. <i>Gastroenterology</i> , 2016, 150, S1046.	0.6	0
331	Reply to J. Cabezas et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 290-291.	0.8	0
332	Integrated Analysis of Controlled Clinical Trials Evaluating Efficacy and Safety of Sofosbuvir-Based Regimens in Chronic Hepatitis C Genotype 6 (HCV GT 6). <i>Gastroenterology</i> , 2017, 152, S1094.	0.6	0
333	Response to Cytoplasmic rods and rings in ribavirin and Cytoplasmic rods and rings in mycophenolic acid treatment.. <i>Liver International</i> , 2017, 37, 1743-1744.	1.9	0
334	The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development. <i>Current Hepatology Reports</i> , 2018, 17, 97-104.	0.4	0
335	Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice. <i>Current Hepatology Reports</i> , 2018, 17, 444-450.	0.4	0
336	PS-056-Higher relapse and retreatment rates in patients who started as HBeAg positive than negative after stopping long-term nucleos(t)ide analogue therapy: results from the randomized controlled STOP study. <i>Journal of Hepatology</i> , 2019, 70, e34.	1.8	0
337	THU-305-Comparing perceptions of illness among patients with chronic liver disease. <i>Journal of Hepatology</i> , 2019, 70, e294-e295.	1.8	0
338	FRI-170-Real-world effectiveness and renal safety of tenofovir alafenamide fumarate among chronic hepatitis B patients in Canada. <i>Journal of Hepatology</i> , 2019, 70, e463-e464.	1.8	0
339	FRI-226-Modeling early viral kinetics during observed HCV acute infection in post lung transplantation recipients. <i>Journal of Hepatology</i> , 2019, 70, e494-e495.	1.8	0
340	FRI-257-Making OraQuick quicker: A hepatitis C point-of-care assay reduced to five minutes for viremic individuals. <i>Journal of Hepatology</i> , 2019, 70, e507.	1.8	0
341	PS-189-Toronto HCC risk index and albumin predict low risk of hepatocellular carcinoma after sustained virological response in hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e116-e117.	1.8	0
342	THU-154-Low rate of hepatitis B reactivation among patients with chronic hepatitis C during direct acting antiviral therapy. <i>Journal of Hepatology</i> , 2019, 70, e229-e230.	1.8	0

#	ARTICLE	IF	CITATIONS
343	Controversies in Treating Chronic Hepatitis B Virus Infection. Clinics in Liver Disease, 2021, 25, 805-816.	1.0	0
344	Screening for hepatitis B virus (HBV) prior to chemotherapy: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2011, 29, 6059-6059.	0.8	0
345	Hepatitis B reactivation in patients with lymphoma: A meta-analysis.. Journal of Clinical Oncology, 2013, 31, 228-228.	0.8	0
346	An electronic prompt prior to myelosuppressive therapy to improve hepatitis B virus screening.. Journal of Clinical Oncology, 2014, 32, 6627-6627.	0.8	0
347	Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis.. Journal of Clinical Oncology, 2015, 33, 6617-6617.	0.8	0
348	Implications of Manganese in Chronic acquired hepatocerebral degeneration. Annals of Hepatology, 2018, 17, 0-10.	0.6	0
349	Hepatitis C models of care: approaches to elimination. Canadian Liver Journal, 2020, 3, 165-176.	0.3	0
350	Characterization of HCV-infected people who inject drugs (PWID) in the setting of clinical care in Canada (CAPICA): A retrospective study. Canadian Liver Journal, 2020, 3, 358-371.	0.3	0
351	An update from the Canadian Association for the Study of the Liver on the management of liver disease during the COVID-19 pandemic. Canadian Liver Journal, 2020, 3, 309-321.	0.3	0
352	A tribute to Dr Saya Victor Feinman. Canadian Liver Journal, 0, , .	0.3	0
353	Successful use of a hepatitis C viremic donor in pediatric bilateral lobar lung transplantation. JTCVS Techniques, 2022, , .	0.2	0
354	Practical Implementation of Universal Hepatitis B Virus Screening for Patients With Cancer. JCO Oncology Practice, 0, , .	1.4	0